Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Direxion Daily S&P 500 Bear 3X Shares ETF
SPXS
5
T-Rex 2x Inverse Tesla Daily Target ETF
TSLZ
US Stock MarketDetailed Quotes
AVTX Avalo Therapeutics
- 4.780
- -0.100-2.05%
Close Apr 25 16:00 ET
51.01MMarket Cap-0.23P/E (TTM)
4.890High4.630Low23.05KVolume4.800Open4.880Pre Close110.15KTurnover0.63%Turnover RatioLossP/E (Static)10.67MShares16.00052wk High0.38P/B17.60MFloat Cap4.15052wk Low--Dividend TTM3.68MShs Float22031.712Historical High--Div YieldTTM5.33%Amplitude3.950Historical Low4.777Avg Price1Lot Size
About Avalo Therapeutics Company
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
Company Profile
SymbolAVTX
Company NameAvalo Therapeutics
Listing DateNov 13, 2015
Founded2011
CEODr. Garry A. Neil, M.D.
MarketNASDAQ
Employees23
Fiscal Year Ends12-31
Address540 Gaither Road,Suite 400
CityRockville
ProvinceMaryland
CountryUnited States of America
Zip Code20850
Phone1-410-522-8707
Websitehttp://www.avalotx.com
Company Executives
- Name
- Position
- Salary
- Dr. Garry A. Neil, M.D.
- Director, President and Chief Executive Officer
- 1.08M
- Jennifer Riley
- Chief Strategy Officer
- --
- Paul Varki
- Chief Legal Officer
- --
- Christopher Ryan Sullivan
- Chief Financial Officer and Principal Accounting Officer
- 607.65K
- Dr. Mittie Doyle, F.A.C.R.,M.D.
- Chief Medical Officer
- --
- Michael T. Heffernan, R.Ph.
- Chairman of the Board
- --
- Samantha Truex
- Independent Director
- --
- Mitchell Chan
- Independent Director
- 60.12K
- Aaron Kantoff
- Independent Director
- --
- Dr. June S. Almenoff, F.A.C.P.,M.D.,PhD
- Independent Director
- 59.12K
- Dr. Jonathan Goldman, M.D.
- Independent Director
- --
- Dr. Gilla Kaplan,PhD
- Independent Director
- 60.12K
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call